Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7649268 | 0.93 | ADORA1 (0.72) | ADORA1SLC6A3 | |
| SCHEMBL7602035 | 0.92 | ADORA1 (0.65) | ADORA1SLC6A3 | |
| SCHEMBL7604784 | 0.92 | ADORA1 (0.67) | ADORA1SLC6A3 | |
| Hydrochloric Acid SCHEMBL3703225 | 0.92 | ADORA1 (0.71) | ADORA1SLC6A3 | |
| SCHEMBL7606724 | 0.92 | ADORA1 (0.63) | ADORA1SLC6A3 | |
| SCHEMBL7604778 | 0.92 | ADORA1 (0.64) | ADORA1SLC6A3 | |
| SCHEMBL7604770 | 0.90 | ADORA1 (0.63) | ADORA1SLC6A3 | |
| SCHEMBL7603710 | 0.90 | ADORA1 (0.63) | ADORA1SLC6A3 | |
| SCHEMBL7606861 | 0.90 | ADORA1 (0.59) | ADORA1SLC6A3 | |
| SCHEMBL7606720 | 0.90 | ADORA1 (0.62) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133364-A1 | DIPEPTOID PRODRUGS AND THEIR USE | BAYER IP GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
| US-8957017-B2 | Dipeptoid prodrugs and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20140206879-A1 | DIPEPTOID PRODRUGS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-24 | — | — | US | disclosed |
| US-8703696-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-20120122820-A1 | PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2012-05-17 | — | — | US | disclosed |
| US-20110294718-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122820-A1 | PRODRUGS AND THE USE THEREOF | TPMT, DPP4, PYGL | ADORA1 1087/4885SLC6A3 825/4885 |
| US-20140206879-A1 | DIPEPTOID PRODRUGS AND THEIR USE | DPP4, DPP3, DPP7 | ADORA1 755/4885SLC6A3 612/4885 |
| US-20110294718-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DPP7 | ADORA1 826/4885SLC6A3 594/4885 |
| US-20150133364-A1 | DIPEPTOID PRODRUGS AND THEIR USE | DPP4, DPP3, DPP7 | ADORA1 755/4885SLC6A3 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.